The bioproduction sector is facing a pivotal year in 2026, with technological innovation, regulatory divergence, and sustainability driving new manufacturing paradigms amid soaring demand for advanced biologics.
The bioproduction sector is accelerating into a more complex era as cell and gene therapies (CGT), multispecific biologics and antibody‑drug conjugates (ADCs) move from experimental niches toward broader commercialisation. According to a Trends for 2026 featur...
Continue Reading This Article
Enjoy this article as well as all of our content, including reports, news, tips and more.
By registering or signing into your SRM Today account, you agree to SRM Today's Terms of Use and consent to the processing of your personal information as described in our Privacy Policy.
Industry analyses and market reports released in 2025 reinforce that picture while adding sharper warnings about capacity, cost and resilience. Biocompare finds more than 60% of early‑stage molecules are now novel monoclonal antibodies or CGTs, underlining a decisive reallocation of innovation and capital away from traditional large‑molecule pipelines. Alira Health projects the CGT market will exceed $25 billion by 2026, growing at roughly a 30% compound annual rate, a surge that is driving unprecedented demand for specialised contract development and manufacturing organisations (CDMOs). According to the Alira Health report, that demand brings heavy capital requirements, stringent oversight and supply vulnerabilities that threaten operational stability.
The economics of scale are stark. A 2025 market outlook cited by 24Life Sciences notes that establishing state‑of‑the‑art biologics facilities can require investments that exceed $500 million, while evolving quality standards and regulatory changes have added an estimated 15–20% to development costs and can delay market entry. Those pressures are visible in industry sentiment: a 2025 Cytiva survey, reported by Pharma Manufacturing, recorded a decline in manufacturing resilience scores and found that 40% of executives believe cost‑cutting has compromised product quality, while 36% said process changes were driven more by cost than by quality considerations.
Technical bottlenecks are already forcing innovation across the value chain. As Lynch and others have observed, living‑cell modalities and complex multispecific molecules place new demands on raw materials, consumables and process controls, and they strain conventional facility designs. PharmaFocus America documents advances in downstream processing, multimodal chromatography resins and automated continuous chromatography platforms among them, that aim to relieve purification choke points. Similarly, closed‑system platforms and large‑scale T‑cell expansion technologies are being developed to meet CGT throughput requirements.
Digital technologies are central to those responses. A BioSpace market outlook highlights the growing role of artificial intelligence and digital innovation to improve process efficiency and quality control in CGT manufacturing, while Genetic Engineering & Biotechnology News emphasises the move of process analytical technology and advanced analytics from laboratory research into routine production. The expected benefits include real‑time monitoring, predictive maintenance and faster technology transfer, which are crucial as outsourcing and CDMO partnerships increase.
Yet digital adoption is not a panacea. The BioSpace report also cautions that AI and analytics must contend with high manufacturing costs, complex production processes and shortages of suitably skilled staff, factors echoed in the Cytiva survey’s identification of talent gaps and regulatory fragmentation as drivers of reduced manufacturing agility.
Geopolitics and regulatory divergence add further complexity. Genetic Engineering & Biotechnology News and other industry sources point to Asia’s growing role as an innovation and manufacturing hub, notably China and Singapore, driven by fresh investment and expanding talent pools. At the same time, stakeholders warn that a lack of harmonised standards for GMP‑compliant materials, process validation and quality control complicates global supply chains and cross‑border collaboration. The cumulative effect is a stronger need for coordinated risk management and regulatory engagement.
Sustainability is now embedded in strategic choices. Life‑cycle assessments cited in the lead article indicate single‑use systems can deliver substantial reductions in water and energy consumption versus stainless‑steel workflows; one study found water use fell by 87% and energy use by 29% at a 2,000 L scale. Lynch emphasises that such systems also offer flexibility for small‑volume and personalised therapies, while industry programmes continue to explore recycling and circular‑economy measures to temper single‑use waste streams.
Taken together, the evidence points to several priorities for 2026. First, investment in flexible, modular manufacturing, single‑use technologies, intensified processes and digital operations, will remain essential to accommodate diverse modalities and accelerate scale‑up. Second, the CDMO ecosystem must expand capacity while navigating high capital barriers and tighter regulatory burdens. Third, interoperability of data and harmonisation of standards will be critical to preserve quality and accelerate global supply chains. Finally, organisations must balance rapid innovation with workforce development and resilient procurement strategies to prevent cost pressures from eroding quality.
The events of 2025 exposed both the industry’s agility and its fragilities: new modalities are nearer to patients, but commercial success will depend on coordinated investment, regulatory alignment and the intelligent integration of digital tools. As Genetic Engineering & Biotechnology News notes, the choices made now about platforms, partnerships and standards will determine how effectively bioproduction converts scientific promise into widely accessible therapies.
Source: Noah Wire Services
Subscribe to Industry Updates
